Table 3.

Rucaparib’s Ongoing Clinical Trials for Prostate Cancer

Clinicaltrials.Gov Identification Number and Name (if Applicable)	Phase of and Type of Clinical Trial	Condition Treated and Details (if Applicable)	Mutations tested (if Applicable)	Interventions Tested (Arms)	Start Date	Projected Primary Completion Date
TRITON3, NCT02975934	Phase III, multi-arm, open-label	mCRPC, with previous next generation ARAT	BRCA1/2 or ATM	Rucaparib vs Abiraterone or Enzalutamide or Docetaxel	June 2017	June 2022 (no results posted as of July 2022)
PLATI-PARP, NCT03442556	Phase II, single-arm, open-label	mCRPC, with some prior therapy as long as it does not include a PARP inhibitor or platinum chemotherapy	Any pathogenic or inactivating alteration in a gene associated with HRR	Induction Carboplatin and Docetaxel followed by maintenance with Rucaparib	August 2018	May 2025
TRIUMPH, NCT03413995	Phase II, single-arm, open-label	mHSPC, without prior ADT treatment (either ineligible for or declined ADT therapy). The trial would provide an alternative to ADT	Germline mutation in one or more of the following HRR genes (BRCA1/2, ATM, CHEK2, NBN, RAD50, RAD51C, RAD51D, PALB2, MRE11, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM)	Rucaparib	September 2018	December 2022
ROAR, NCT03533946	Phase II, single-arm, open-label	nmHSPC	Mutation in one of the following HRR-associated genes (BARD1, BRCA1/2, BRIP1, CHEK1, CHEK2, FANCA, NBN, PALB2, RAD51C, RAD51D, RAD51, RAD51B)	Rucaparib	May 2019	July 2023
LODESTAR, NCT04171700	Phase II, single-arm, open-label	Any solid tumor	Somatic or germline deleterious mutation in a HRR gene (BRCA1/2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B)	Rucaparib	November 2019	May 2022
RAMP, NCT04179396	Phase Ib, multi-arm, open-label	mCRPC, with or without previous ARAT	N/A	Rucaparib and enzalutamide vs Rucaparib and abiraterone	December 2019	November 2022
BrUOG 360, NCT04253262	Phase Ib/II, single-arm with multiple dose measurements, open-label	mCRPC, with previous abiraterone, enzalutamide, and/or aplutamide therapy	N/A	Rucaparib and Copanlisib together with varying doses of both – objective is to find maximal tolerable dose to then test in Phase II part of study	April 2020	July 2021 (no results posted as of July 2022)
CASPAR, NCT04455750	Phase III, multi-arm, double-blinded	mCRPC, with no prior therapy for mCRPC at the time of registration, meaning that the patient had not had major surgery or radiation for ≥4 weeks, had not been on investigational therapy for ≥4 weeks or 5 half-lives (the shorter period), and had not been on flutamide, dutasteride, bicalutamide, niltamide, finasteride, aminoglutethimide, estrogens, cytoproterone, chemotherapy, abiraterone, apalutamide, or darolutamide for ≥4 weeks or 5 half-lives (the shorter period). Moreover, prior docetaxel and/or ARAT was allowed only if for nmHSPC, mHSPC, or nmCRPC. No prior therapy with enzalutamide, PARP inhitors, or platinum chemotherapy was allowed.	N/A	Enzalutamide and Rucaparib vs Enzalutamide and Placebo If patient has not undergone bilateral orchiectomy ADT is included (both arms)	February 2021	May 2023
CATCH-R, NCT04676334	Phase III, single-arm, open-label (maintenance therapy for patients currently benefitting from rucaparib)	mCRPC, ovarian cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, other solid tumor	N/A	Rucaparib	March 2021	November 2023

Note: Data from Wei et al.⁵⁷

Abbreviations: mCRPC, metastatic castrate-resistant prostate cancer; ARAT, androgen receptor-axis-targeted therapies; PARP, poly(adenosine diphosphate-ribose) polymerase; HRR, homologous recombination repair; mHSPC, metastatic hormone sensitive prostate cancer; ADT, androgen deprivation therapy; nmHSPC, non-metastatic hormone sensitive prostate cancer; nmCRPC, non-metastatic castration-resistant prostate cancer.